Multiple myeloma involves a comprehensive approach that combines blood tests, imaging, and bone marrow studies. Learn about ...

Mail: vasilis.ntziachristos@helmholtz-munich.de Gasparin et al., 2025: Label-free protein-structure-sensitive live-cell microscopy for patient-specific assessment of myeloma therapy. Nature Biomedical ...

Multiple myeloma is a rare blood cancer of the plasma cells in bone marrow -- the soft, spongy interior of bone where all blood cells are produced. Plasma cells are a type of white blood cell that ...

A multi-institutional study led by the Icahn School of Medicine at Mount Sinai reports one-third of patients with relapsed or refractory multiple myeloma remained in remission for at least five ...

A breakthrough in cancer treatment in the Valley: CARVYKTI therapy is helping Arizonans with multiple myeloma live longer, healthier lives.

A new standard of care Newly diagnosed multiple myeloma patients at Sylvester and other cancer centers are already routinely receiving the four-drug DKRd combination.

Johnson & Johnson has won the support of an FDA expert panel in its bid to make Darzalex the first treatment for an early form of multiple myeloma despite uncertainties raised by regulators.

Cemsidomide led to strong responses at multiple doses in patients with multiple myeloma, including one complete response with no minimal residual disease detected.

Predicta Biosciences, a precision oncology company developing novel diagnostic and therapeutic products, today announced the availability of its first Labora ...

The company plans to expand beyond multiple myeloma, offering precision diagnostic products for other common blood cancers and autoimmune diseases. About Predicta Biosciences ...

For decades, the diagnosis of multiple myeloma required evidence of end-organ damage characterized by myeloma-defining events ...